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Deltex-1 mutations predict poor survival in diffuse
large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a group of
clinically aggressive and heterogeneous malignancies, of
which approximately 60% can be cured with anthracy-
cline-based chemoimmunotherapy.  Based on gene
expression profiling, DLBCL can be classified into two
molecularly distinct subgroups showing germinal center
B-cell (GCB) and activated B-cell (ABC) lymphoma signa-
tures,1,2 which differ in their genotypic, phenotypic and
clinical features.  Recently, studies applying next genera-
tion sequencing (NGS) techniques have provided further
insights into the heterogeneity and pathogenesis of
DLBCL.3 Many recurrent mutations have been identified
as drivers of lymphoma pathogenesis,3 yet their associa-
tion with survival remains to be established. It is also
likely that other mutations, which do not contribute to
lymphomagenesis per se, but rather predispose to a more
drug-resistant disease and poor survival, will be recog-
nized.
To identify mutations that contribute to the clinical
outcome of DLBCL patients, we performed whole exome
sequencing for 8 primary lymphoma samples and
matched normal DNA. The patients were clinically at
high-risk of relapse [age-adjusted International
Prognostic Index (aaIPI)]. A total of 922 somatic point
mutations and insertion-deletions in 838 different genes
were identified (Online Supplementary Figure S1). Several
of them were detected in established oncogenes recur-
rently mutated in DLBCL, including MYD88, MEF2B and
B2M.3 Fifty-one genes were mutated in at least 2 patients
including lymphoma related genes CD79B, PTEN and
DTX1. 
For validation and correlation of the findings with sur-
vival we used a Cancer Genome Characterization
Initiative (CGCI) cohort of 92 DLBCL patients (Figure
1A).4 The clinical characteristics of the cohort are shown
in Table 1. Of the 838 genes, which were mutated in our
initial screen, 456 genes were also mutated in the CGCI
cohort. Using three different filtering approaches to
exclude germline polymorphisms and to recognize dis-
ease-causing alterations, mutations in 41 genes were
found to correlate with survival (Online Supplementary
Figure S1). When the variants were filtered with CADD
scoring predicting altered protein function, survival-asso-
ciated mutations were found only in 4 genes, including
DTX1, PIM1, GNA13 and TMSB4X (Online Supplementary
Figure S1). Of these, only the mutations in the DTX1 gene
encoding an E3 ubiquitin ligase and a regulator of the
Notch pathway5-7 were significantly associated both with
time to progression (TTP) and overall survival (OS) with
all the filtering criteria used, and were thus selected for
further analysis.
In our initial exome sequencing screen 3 patients har-
bored mutations in their DTX1 genes, and a total of 8 dif-
ferent non-synonymous mutations were identified
(Online Supplementary Table S2). All the mutations in the
DTX1 gene were validated using targeted capillary
sequencing and confirmed to be somatic. In the CGCI
study population, 14% (Table 1) of the patients were car-
rying non-synonymous DTX1 mutations (Online
Supplementary Table S3). Of these, 2 had 2 mutations in
their DTX1 genes and 1 had 3. Mutations were equally
distributed between GCB and ABC subtypes and clinical
risk groups (Table 1).
For the CGCI cohort, the median follow-up time was
59 months, with TTP, PFS (progression-free survival) and
OS at 5 years of 74%, 72% and 79%, respectively. The
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Table 1. Patient characteristics according to DTX1 mutations in CGCI and Nordic cohorts of DLBCL patients. 
Patient Characteristics CGCI Nordic
DTX1 DTX1
All DTX1 DTX1 P All WWE1 WWE1 P
wt mut wt mut
Sex
Male 61 (66) 51(65) 10(77) 0.532 83 (57) 66(57) 17(59) 1.000
Female 31 (34) 28 (35) 3(23) 62 (43) 50(43) 12(41)
Age
<60 y 39 (42) 35 (44) 4(31) 0.546 82 (57) 68(59) 14 (48) 0.403
>60 y 53 (58) 44 (56) 9 (69) 63 (43) 48 (41) 15 (52)
Stage
I-II 44 (48) 36 (46) 8 (62) 0.373 52 (36) 42 (36) 10 (34) 1.000
III-IV 48 (52) 43 (54) 5 (38) 93 (64) 74 (64) 19 (66)
IPI
Low (0-2) 40 (43) 35 (44) 5(38) 0.770 87 (60) 69 (59) 18 (62) 0.836
High (3-5) 52 (57) 44 (56) 8(62) 58 (40) 47 (41) 11 (38)
Subtype*
GCB 51 (55) 46 (58) 5(38) 68 (47) 57 (49) 11 (38)
ABC/Non-GCB 32 (35) 25 (32) 7(54) 0.234 62 (43) 46 (40) 16 (55) 0.199
Unclassified/NA 9 (10) 8 (10) 1 (8) 15 (10) 13 (11) 2 (7)
Median age in the CGCI and the Nordic cohorts is 61 (range 17-75) and 58 (range, 16-84) years. *In the CGCI cohort, molecular subtyping is based on gene expression pro-
filing allowing for the classification of GCB, ABC and unclassified subtypes, whereas in the Nordic cohort, the classification is based on the Hans algorithm (GCB vs. non-
GCB). NA (not available) refers to the Nordic cohort. IPI: International Prognostic Index; GCB: germinal center B cell; ABC: activated B cell; CGCI: Cancer Genome
Characterization Initiative; wt: wild-type; mut: mutated.
patients with non-synonymous DTX1mutations had sig-
nificantly worse survival in comparison to the patients
with wild-type DTX1 (Figure 1B). When DTX1mutations
were analyzed according to different functional protein
domains, a substantial enrichment of mutations (11 out
of 16, 65%) was observed in the WWE1-domain (Figure
1C). In Kaplan-Meier and Cox regression analyses,
decreases in TTP, PFS and OS rates were observed, if a
mutation was located in the WWE1 domain (TTP,
RR=4.533, 95% CI 1.684-12.207, P=0.003; PFS,
RR=3.831, 95% CI 1.443-10.170, P=0.007; OS,
RR=3.551, 95% CI 1.192-10.574, P=0.023; Figure 1D). 
To validate the survival association of the non-synony-
mous mutations in the DTX1 WWE1 domain, we
expanded our initial screening cohort to a ‘Nordic cohort’
of 145 DLBCL patients (Figure 1A). Non-synonymous
mutations in the DTX1 WWE1 domain were detected in
20% of the samples (29/145) (Figure 1C, Online
Supplementary Table S4). Consistent with the CGCI
cohort, WWE1 mutations were equally distributed
between molecular and clinical risk groups (Table 1). The
median follow-up time for the whole cohort was 62
months (range 3-133 months). 5-year TTP, PFS and OS
rates were 73%, 69%, and 77%, respectively. However,
for the patients with non-synonymous WWE1 domain
mutations of DTX1 , survival rates at 5 years were signif-
icantly worse than for the patients without mutations
(Figure 1E). In Cox multivariate analysis with an IPI
score, DTX1 WWE1 mutations remained independent
prognostic factors for TTP and OS (Table 2). Collectively,
the results in our two independent cohorts show that the
mutational status of the DTX1 WWE1 domain is a novel
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Figure 1. DTX1 mutations are enriched in the first exon encoding the WWE 1 domain and predict survival in DLBCL. (A) Flow of the study. (B) OS in the CGCI
cohort according to DTX1 mutations. (C) Structure of the DTX1 gene and localization of the DTX1 mutations in the CGCI and Nordic cohorts. (D) OS in the CGCI
cohort according to mutations in the DTX1 WWE1 domain. (E) OS in the Nordic validation cohort according to mutations in the DTX1 WWE1 domain. DLBCL: dif-






5-year OS 85% vs. 45%
5-year OS 85% vs. 43%
5-year OS 81% vs. 62%
P=0.015
P=0.038
negative predictor of survival in DLBCL.
To examine DTX1 expression in the lymphoma tissue
and localization in different cellular compartments, we
extended our analyses to the protein level. In the normal
lymph node, DTX1 immunoreactivity was cytoplasmic
and primarily localized to germinal center B-cells with
centroblast morphology (Online Supplementary Figure
S2A). In DLBCL tissue, the staining intensity varied
between the samples, but otherwise resembled that of
normal centroblasts (Online Supplementary Figure S2B).
Interestingly, the samples carrying DTX1 mutations
showed significantly lower protein levels (t-test, P=0.007;
Online Supplementary Figure S2C-D). 
Further examination of DTX1 mutations and gene
expression in the CGCI repository confirmed that the
samples carrying DTX1 mutations showed significantly
lower DTX1 expression (t-test, P=0.011; Online
Supplementary Figure S2E). In addition, DTX1 expression
was significantly higher in the GCB than the ABC type
DLBCLs (t-test, P=0.009). The association was further
validated in the Lymphoma/Leukemia Molecular
Profiling Project  (LLMPP) cohort1 of 233 patients with
DLBCL (t-test, P<0.001).
To identify genes that were anti-expressed and co-
expressed with DTX1, we computed Pearson's correla-
tion between DTX1 expression levels and other genes
across 92 samples in the CGCI data set, which resulted in
471 inversely and 1832 positively correlated genes.
Among the inversely correlated genes were, for example,
JAK2, CASP10, CD47, b2M and INFGR1, while BCL6,
PRKCA, RCOR1, CD22, and KMT2B, were among the
positively correlated ones. To identify biological path-
ways associated with the DTX1 expression signature, we
performed a pathway enrichment analysis for anti-
expressed and co-expressed genes. The genes inversely
correlated with DTX1 were enriched, for example, for
proteasomal degradation, IFN-γ signaling and JAK-STAT
pathways (Online Supplementary Table S5), whereas posi-
tively correlated pathways included, for instance, chro-
matin remodeling, B-cell receptor (BCR) signaling and
mitogen-activated protein kinase (MAPK) pathways
(Online Supplementary Table S6). In addition, Notch signal-
ing pathway effectors were found to correlate with DTX1
expression. 
DTX1 is an ubiquitin E3 ligase containing N-terminal
Notch binding WWE domains, a proline-rich motif and a
C-terminal really interesting new gene (RING) finger
domain commonly found in ubiquitin E3 ligases.5-7 DTX1
mediates Notch activation in Drosophila, but its exact
role in Notch signaling in mammals has remained largely
ambiguous. Interestingly, in the hematological context,
DTX1 can negatively regulate T-cell activation by target-
ing mitogen-activated protein kinase kinase kinase 1
(MEKK1 or MAP3K) and protein kinase C Θ for degrada-
tion,8,9 and mediate degradation of hypoxia-inducible fac-
tor-1α (HIF-1α) in regulatory T cells (Tregs).10 However,
in normal B cells and lymphomas, the function of DTX1
and the impact of mutations remain to be established.
Somatic hypermutation has been predicted to aberrantly
target the DTX1 gene,11 and DTX1 mutations have previ-
ously been reported in follicular and splenic marginal
zone lymphomas.12,13 Furthermore, DTX1mutations were
also recently identified in a cohort consisting of Chinese
patients with primary and relapsed DLBCL.14 Consistent
with our findings, the mutations were almost exclusively
localized to the WWE1 domain of the protein, and based
on the Notch reporter gene assay in U2OS osteosarcoma
cells, it was suggested that deleterious mutations impair
the function of DTX1 as a negative regulator of Notch.
Our pathway enrichment analyses support the idea that
there is a functional connection between DTX1 and the
Notch pathway. In addition, we identify other novel and
potentially relevant associations. However, functional
studies should be performed to establish the biological
relevance of these findings. 
In conclusion, we have used well characterized DLBCL
patient cohorts to identify survival associated mutations
in DLBCL, and validated the findings in a large and inde-
pendent patient cohort. To our knowledge, this is the first
report to examine the prognostic impact of DTX1 aberra-
tions in lymphomas. While further investigation of the
molecular mechanisms driven by DTX1 mutations
remain to be established, our results indicate that these
aberrations in the DTX1 gene have a tumor-promoting
role in DLBCL. Taken together, the results presented
herein are promising and novel, and demonstrate that
mutational status at diagnosis can provide prognostic
value, independent of IPI, and improve risk stratification
in DLBCL. (clinicaltrials.gov Identifier: 01502982)
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Table 2. Cox multivariate models for DTX1 mutations in the Nordic cohort.
Survival TTP OS
Variable RR 95% CI P RR 95% CI P
DTX1 (wt vs.WWE1 mutated) 2.140 1.102-4.154 0.025 2.114 1.050-4.255 0.036
IPI 1.434 1.095-1.878 0.009 1.482 1.110-1.980 0.008
DTX1 mutational status, mutated worse; IPI, higher IPI worse. RR: relative risk; CI: confidence interval; IPI: International Prognostic Index; TTP: time to progression; OS: over-
all survival; wt: wild-type.
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